

Eunice Kennedy Shriver
National Institute of Child Health and Human Development
National Institutes of Health
Best Pharmaceuticals for Children Act

2009 Antipsychotic Drug Therapeutics Working Group
Supplemental References
April 2014

- Calarge, C.A., Acion, L. & Schlechte, J.A. (2009). Weight Gain and Metabolic Abnormalities During Extended Risperidone Treatment in Children and Adolescents. *J Child Adolesc Psychopharmacol*, 19(2), 101-109.
- Clinical Impact of Adverse Event Reporting. *MedWatch*. Retrieved 2009 from <http://www.fda.gov/downloads/safety/medwatch/ucm168505.pdf>.
- Cooper, W.O., Habel, L.A., Sox, C.M., Chan, A., Arbogast, P.G., Cheetham, C...Ray, W.A. (2011). ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults. *N Engl J Med*, 365(20),1896-1904.
- Correll C.U., Manu, P., Olshanskiy V., Napolitano B., Kane, J.M., & Malhotra, A.K. (2009). Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. *JAMA*, 302(16),1765-1773.
- Korelitz, J.J., Zito, J.M., Gavin, N.I., Masters, M.N., McNally, Irwin D.E...Mattison, D.R. (2008). Asthma-Related Medication Use among Children in the United States. *Science Direct*, 100(3), 222–229.
- Lieberman, J.A. and Stroup, T. S. The NIMH-CATIE Schizophrenia Study: What Did We Learn? *Amer J Psychiatry*, 168(8), 770-775.
- Olfson, M., Blanco, C., Liu, L., Moreno, C., & Laje, G. (2006). National Trends in the Outpatient Treatment of Children and Adolescents with Antipsychotic Drugs. *Arch Genl Psychiatry*, 63, 679-685.
- Schneider, L.S., Tariot, P.N., Dagerman, K.S., Davis, S.M., Hsiao, J.K, Ismael, S.M...Lieberman, J.A. (2006). Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. *New Engl J Med*, 355(15), 1525-1538.
- Shin, L., Bregman, H., Breeze, J.L., Noyes, N., & Frazier, J.A. Metformin for Weight Control in Pediatric Patients on Atypical Antipsychotic Medication. *J Child Adoles Psychopharm*, 19(3), 275-279.
- Winterstein, A.G., Gerhard, T., Shuster, J., Johnson, M., Zito, J.M., & Saidi, A. (2008). Cardiac Safety of Central Nervous System Stimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. *Pediatrics*, 120(6), e1494-1501.
- Woods, S.W., Martin, A., Spector, S.G., & McGlashan, T.H. (2002). Effects of Development on Olanzapine-Associated Adverse Events. *J Am Acad Child Adolesc Psychiatry*, 41(12), 1439-46.